TY - JOUR
T1 - Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors:
T2 - A multi-center, retrospective analysis
AU - Grey (nee Cotte), Steffi
AU - Salmen (nee Stroet), Anke
AU - von Ahsen, Nico
AU - Starck, Michaela
AU - Winkelmann, Alexander
AU - Zettl, Uwe K.
AU - Comabella, Manuel
AU - Montalban, Xavier
AU - Zipp, Frauke
AU - Fleischer, Vinzenz
AU - Kruse, Niels
AU - Gold, Ralf
AU - Chan, Andrew
PY - 2015/1/15
Y1 - 2015/1/15
N2 - Background: Mitoxantrone is used on an off-label basis in primary progressive MS (PPMS).ABC-transporter-genotypes are associated with therapeutic response in relapsing/secondary progressive MS (RP/SPMS).Objective: To evaluate potential pharmacogenetic response markers for mitoxantrone in PPMS.Methods: 41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1- and ABCG2-genes.Results: 53.7% PPMS-patients were mitoxantrone-responders, in comparison to 78.1% of RP/SPMS-patients (p = 0.039). There was no association between genotype and treatment response.Conclusion: Our data discourages the use of mitoxantrone in PPMS regardless of pharmacogenetic response markers previously described in RP/SPMS. (C) 2014 Elsevier B.V. All rights reserved.
AB - Background: Mitoxantrone is used on an off-label basis in primary progressive MS (PPMS).ABC-transporter-genotypes are associated with therapeutic response in relapsing/secondary progressive MS (RP/SPMS).Objective: To evaluate potential pharmacogenetic response markers for mitoxantrone in PPMS.Methods: 41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1- and ABCG2-genes.Results: 53.7% PPMS-patients were mitoxantrone-responders, in comparison to 78.1% of RP/SPMS-patients (p = 0.039). There was no association between genotype and treatment response.Conclusion: Our data discourages the use of mitoxantrone in PPMS regardless of pharmacogenetic response markers previously described in RP/SPMS. (C) 2014 Elsevier B.V. All rights reserved.
KW - Escalation therapy
KW - Immunosuppression
KW - Multi-drug resistance transporter
KW - Pharmacogenetics
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=uab_pure&SrcAuth=WosAPI&KeyUT=WOS:000349269300035&DestLinkType=FullRecord&DestApp=WOS
UR - https://www.scopus.com/pages/publications/84920896770
U2 - 10.1016/j.jneuroim.2014.11.017
DO - 10.1016/j.jneuroim.2014.11.017
M3 - Article
C2 - 25468777
SN - 0165-5728
VL - 278
SP - 277
EP - 279
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
ER -